NEIL D. GROSS, M.D.

Assistant Professor,

Head and Neck Surgery and Oncology

Research:

“I have a passion for clinical care and relish the opportunity to make a direct impact on the lives of patients with head and neck cancer.  Although primarily trained as a surgeon, I am keenly aware that future gains in cancer patient outcomes are dependent upon non-surgical discoveries.  Therefore, I am dedicated to cancer research as an integral part of my career.”

Multidisciplinary Clinical Trials and Other Research at OHSU for Head and Neck Cancer Patients

Assessment of Known and Candidate Cancer Genes through DNA Analysis, RNA Expression and Protein Function Testing to Predict Patient Prognosis and Response to Current Standard and Experimental Therapies. (IRB# 809)
Principal Investigator: Molly Kulesz-Martin, Ph.D.

RTOG 0514: Establishment of a Head and Neck Tissue/Specimen Bank. (IRB#2928)
Supported by the National Cancer Institute
Principal Investigator: Neil Gross, M.D.

An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-Based Chemotherapy. (IRB# 3893)
Sponsored by Genmab A/S.
Institutional Principal Investigator: Neil Gross, M.D.

Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma. (IRB# 3914)
Sponsored by ImClone, Inc.
Principal Investigator: Neil Gross, M.D.

RTOG 0619: A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck. (IRB #5140)
Supported by the National Cancer Institute
Principal Investigator: Neil Gross, M.D.

HPV Oral Transmission Study in Partners Over Time (HOTSPOT). (IRB #5263)
Supported by the Johns Hopkins School of Public Health
Principal Investigator: Neil Gross, M.D.

UPCI 07-124: Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family Kinases Using Erlotinib and Dasatinib in Head and Neck and Lung Cancers. (IRB #5096)
Supported by UPMC SPORE in head and neck cancer, University of Pittsburgh, OSI Pharmaceuticals, and Bristol-Meyers Squibb
Principal Investigator: Neil Gross, M.D.

M06-10083: Phase I Trial of Intratumoral Administration of HF10, a Replication-Competent Herpes Simplex Virus Type 1, in Patients with Refractory Head and Neck Cancer. (IRB #5265)
Sponsored by M’s Science Corporation
Principal Investigator: Neil Gross, M.D.

THYROID

OXiGENE OXC4T4-302: A Multicenter, Open-label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin in Comparison with Paclitaxel and Carboplatin Against Anaplastic Thyroid Cancer. (IRB# 3821)
Sponsored by OXiGENE
Principal Investigator: Ann Gramza, M.D.

Phase 1/2 Study of CS-7017, and Oral PPARy Agonist, in Combination with Paclitaxel in Subjects with Advanced Anaplastic Thyroid Cancer (CS7017-A-U103) (IRB# 4274)
Principal Investigator: Ann Gramza, M.D.